545 related articles for article (PubMed ID: 28538267)
1. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
2. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
4. Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy.
Li XY; You X; Jie YS; Lin GL; Wu YK; Huang MX; Zhang M; Li ZY; Xie DY; Gao ZL; Chong YT
Am J Ther; 2017 May; 24(3):e250-e258. PubMed ID: 25923228
[TBL] [Abstract][Full Text] [Related]
5. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
7. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
9. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
[TBL] [Abstract][Full Text] [Related]
11. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.
Ye XG; Su QM
World J Gastroenterol; 2013 Oct; 19(39):6665-78. PubMed ID: 24151397
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
Law ST; Lee MK; Li KK; Mok CK
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
[TBL] [Abstract][Full Text] [Related]
13. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
Ko SY; Choe WH; Kwon SY; Kim JH; Seo JW; Kim KH; Lee CH
Scand J Gastroenterol; 2012 Nov; 47(11):1362-7. PubMed ID: 22934534
[TBL] [Abstract][Full Text] [Related]
14. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
Kim HR; Yim HJ; Kang S; Suh SJ; Kim SY; Hyun JJ; Koo JS; Kim JH; Seo YS; Yeon JE; Lee SW; Byun KS; Um SH
Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
[TBL] [Abstract][Full Text] [Related]
16. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
17. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
[TBL] [Abstract][Full Text] [Related]
18. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients.
Peng CY; Hsieh TC; Hsieh TY; Tseng KC; Lin CL; Su TH; Tseng TC; Lin HH; Wang CC; Kao JH
J Formos Med Assoc; 2015 Apr; 114(4):308-13. PubMed ID: 24315616
[TBL] [Abstract][Full Text] [Related]
19. Association of virological breakthrough and clinical outcomes in entecavir-treated HBeAg-positive chronic hepatitis B.
Huang YJ; Yang SS; Yeh HZ; Chang CS; Peng YC
PLoS One; 2019; 14(8):e0221958. PubMed ID: 31469875
[TBL] [Abstract][Full Text] [Related]
20. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]